Site Navigation

• Home
• About Dr. Mary
• The Practice
• Testimonials
• The Wilsonette Club
• The WNIM Blog
• What's New in Medicine
  • Volume 1
  • Volume 2
  • Volume 3
  • Volume 4
  • Volume 5
  • Volume 6
  • Volume 7
• Contact Dr. Mary

An Accurate Blood Test For Cancer

There is now a blood test, called AMAS that will accurately detect early cancer of all types. The false positive and negative rates are less than 1%. Twenty-one years ago a neuro-chemist, Samuel Bogoch M.D. PhD, discovered an anticancer antibody in the blood of patients with cancer. He named the new anti-gen Malignin, and new antibody Anti-Malignin Antibody. He founded a laboratory in Boston called Oncolab, Inc. the test has been patented, and the FDA has granted permission to market this test.

Doctors will be using the AMAS test around the world.

Indications: A cancer-screening test. With use of AMAS test you will be able to defer or eliminate chest x-rays, sigmoidoscopy, CT scans possibly even mammograms and Pap tests, unless the AMAS test is abnormal.

In differential diagnosis: If there is a shadow on a chest x-ray, a spot in the liver CT scan, a suspicious area on a mammogram, or an enlarged lymphnode on an MRI. If the AMAS test is normal, the lesion in question is not a cancer. AMAS test should reduce the number of invasive biopsies, and reduce the cost of medicine. AMAS is the antibody to Malignin, a 10.000 Dalton polypeptide which has been found to be present in most malignant cells regardless of cell type or location. Unlike tests such as CEA, which measure less well- defined antigens whose serum levels tend to be inconsistant but elevated late in the disease, the AMAS test measures a well-defined antibody whose serum levels rise early in the course of the disease. In some cases, the AMAS test has been positive (elevated) early, i.e. 1 to 19 months before clinical detection. On the other hand, since antibody failure often occurs late in malignancy, elevated antibody is then no longer available as evidence of the presence of antigen and therefore, late in the disease, the AMAS test cannot be used as a diagnostic aid, but may be useful for monitoring. Studies on more than 6000 patients have shown a sensitivity and specificity of AMAS greater than 95%(99% if repeated) . There will be no need for ordering the routine and conventional tests, such as PSA, CEA, Ca-125, x-rays, mammograms, fecal occult tests, Pap tests, colonoscopies etc., unless AMAS is positive.

The test will also be useful in Veterinary medicine.

AMAS is at its best when cancers are just getting started and are still small in size. As a new cancer-screening test, the AMAS will be invaluable. It's probable that all adults will be screened on an annual basis, perhaps beginning at about age 35. Some might be screened even earlier if there is cancer in the family. It was demonstrated that the concentration of AMAS (anti-malignin antibody in serum) is markedly increased within weeks of the occurrence of malignant transformation to clinical breast cancer.

The study involved breast cancer, but the test is valid for all cancer types.

(The Journal of Cellular Biochemistry, 1999)